Valuation: Roche Holding AG

Market Cap 291B 361B 312B 268B 506B 34,290B 511B 3,421B 1,343B 17,157B 1,354B 1,325B 56,822B P/E 2026 *
20.3x
P/E 2027 * 18x
Enterprise Value 302B 374B 324B 278B 524B 35,555B 530B 3,548B 1,392B 17,790B 1,404B 1,373B 58,919B EV / Sales 2026 *
4.82x
EV / Sales 2027 * 4.51x
Free-Float
88.78%
Yield 2026 *
2.74%
Yield 2027 * 2.8%
Current month+0.48%
6 months-8.95%
Current year-1.29%
Current year 311.6
Extreme 311.6
377
1 year 221.3
Extreme 221.3
377
3 years 212.3
Extreme 212.3
377
5 years 212.3
Extreme 212.3
404.1
10 years 202.23
Extreme 202.231
404.1
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 361B
+4.86%-3.32%+52.73%+160.26% 1,043B
+1.04%-2.99%+50.87%+52.38% 621B
+0.98%-6.49%+24.00%+66.66% 435B
-0.11%-4.07%+30.37%+39.73% 293B
+2.52%-8.36%+7.27%+10.32% 251B
+4.57%+5.21%+35.91%+67.64% 220B
-4.32%-12.94%-3.79%-44.56% 201B
-2.58%-0.73%+17.16%+67.46% 164B
+1.57%+2.62%+4.28%-26.30% 147B
Average +0.12%-3.83%+24.31%+43.73% 375.07B
Weighted average by Cap. +0.49%-4.09%+35.06%+75.86%

Financials

2026 *2027 *
Net sales 62.64B 77.59B 67.2B 57.62B 109B 7,378B 110B 736B 289B 3,692B 291B 285B 12,226B 65.47B 81.09B 70.23B 60.22B 114B 7,711B 115B 769B 302B 3,858B 305B 298B 12,778B
Net income 14.51B 17.97B 15.56B 13.34B 25.19B 1,708B 25.47B 170B 66.9B 855B 67.48B 65.99B 2,831B 16.33B 20.23B 17.52B 15.02B 28.36B 1,924B 28.68B 192B 75.33B 962B 75.98B 74.3B 3,188B
Net Debt 10.74B 13.31B 11.53B 9.88B 18.66B 1,265B 18.86B 126B 49.56B 633B 49.98B 48.88B 2,097B 3.96B 4.91B 4.25B 3.64B 6.88B 467B 6.96B 46.57B 18.28B 234B 18.44B 18.03B 773B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
05/08/26 CHF 323.90 0.00% 174,187
04/08/26 CHF 323.90 0.00% 1,126
03/08/26 CHF 323.90 0.00% 6,768
31/07/26 CHF 323.90 0.00% 8,815
30/07/26 CHF 323.90 0.00% 66,563
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
364.70CHF
Average target price
363.92CHF
Spread / Average Target
-0.21%

Quarterly revenue - Rate of surprise